Related Experiment Video

Updated: Jun 1, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Clyde J Wright1, Haresh Kirpalani

  • 1Division of Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. wrightcl@email.chop.edu

Pediatrics
|June 8, 2011
PubMed

Insights

Bronchopulmonary dysplasia (BPD) is a complication of preterm birth. Research is exploring therapies to limit lung inflammation, a key factor in BPD development and treatment.

Area of Science:

  • Neonatal medicine
  • Pediatric pulmonology
  • Inflammation research

Background:

  • Bronchopulmonary dysplasia (BPD) is a common and serious complication following preterm birth.
  • BPD leads to significant long-term respiratory and developmental issues in affected infants.
  • Current therapeutic options for preventing or treating BPD are limited.

Purpose of the Study:

  • To review current understanding of inflammation's role in BPD pathogenesis.
  • To critically evaluate existing therapies for BPD.
  • To highlight novel and promising therapeutic strategies for BPD.

Main Methods:

  • Literature review of recent bench research.
  • Analysis of clinical studies and trials.
  • Assessment of current treatment guidelines and emerging research.

Main Results:

  • Inflammation is a central mechanism in the development of BPD.
  • Existing therapies have shown limited efficacy in preventing or treating BPD.
  • Several new therapeutic targets and approaches are under investigation.

Conclusions:

  • Understanding the inflammatory pathways in BPD is crucial for developing effective treatments.
  • Further research is needed to translate promising findings into clinical practice.
  • Targeting inflammation offers a promising avenue for improving outcomes in preterm infants at risk for BPD.

More Related Videos

Intratracheal Instillation of Stem Cells in Term Neonatal Rats04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...